Clinical Research Directory
Browse clinical research sites, groups, and studies.
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VT7208 in Healthy Participants and MS Patients
Sponsor: Vidya Therapeutics Inc
Summary
Part 1 of this study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of VT7208 in healthy volunteers. Part 2 of this study will be an open-label, randomized study to characterize the effect of food on the pharmacokinetics of VT7208 in healthy volunteers. Part 3 of this study will evaluate the safety of VT7208 as monotherapy in patients with MS.
Official title: A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Dose Escalation Study in Healthy Participants and an Expansion Cohort in Adult Patients With Multiple Sclerosis to Characterize the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VT7208
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2025-08-01
Completion Date
2027-12-31
Last Updated
2025-09-03
Healthy Volunteers
Yes
Conditions
Interventions
VT7208
a small synthetic molecule capsule, oral
Placebo
capsule, oral
Locations (1)
CMAX
Adelaide, South Australia, Australia